| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.05237-11 |
| P8608 | Fatcat ID | release_4gvcyqkhg5ctfgxsenxisndyoq |
| P932 | PMC publication ID | 3195032 |
| P698 | PubMed publication ID | 21896906 |
| P50 | author | Robert W Buckheit | Q114435506 |
| P2093 | author name string | Lu Yang | |
| Karen Watson Buckheit | |||
| P2860 | cites work | Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 |
| Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women | Q24629582 | ||
| Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro | Q24650946 | ||
| Violence against women: global scope and magnitude | Q28214797 | ||
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| Sulfonic acid dyes: inhibition of the human immunodeficiency virus and mechanism of action | Q28318643 | ||
| SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 | Q28346130 | ||
| Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide | Q28378796 | ||
| Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates | Q28379523 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene | Q29615351 | ||
| Development of topical microbicides to prevent the sexual transmission of HIV | Q33625073 | ||
| Whither or wither microbicides? | Q33715907 | ||
| Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. | Q34068078 | ||
| Biologic approaches to the prevention of sexual transmission of human immunodeficiency virus | Q34122386 | ||
| Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 | ||
| PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial | Q34138687 | ||
| Dawn of non-nucleoside inhibitor-based anti-HIV microbicides | Q34487295 | ||
| Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. | Q34768558 | ||
| Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. | Q36593791 | ||
| Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay | Q36803970 | ||
| Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor | Q37072072 | ||
| Microbicide delivery: formulation technologies and strategies. | Q37447846 | ||
| Microbicides and HIV prevention: lessons from the past, looking to the future | Q37633913 | ||
| Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody | Q38476940 | ||
| Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates | Q38949105 | ||
| Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. | Q39551934 | ||
| Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro | Q39851761 | ||
| The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors | Q40042904 | ||
| Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. | Q40060575 | ||
| Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene | Q41148915 | ||
| An assay for HIV infection of cultured human cervix-derived cells | Q41364806 | ||
| Characterization of an HIV-1 Isolate Displaying an Apparent Absence of Virion-Associated Reverse Transcriptase Activity | Q41691433 | ||
| Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses | Q42545418 | ||
| Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions | Q43051081 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5243-5254 | |
| P577 | publication date | 2011-09-06 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides | |
| P478 | volume | 55 |
| Q39152233 | "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches. |
| Q47678273 | A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates |
| Q48130430 | A Search for Dual Action HIV-1 Reverse Transcriptase, Bacterial RNA Polymerase Inhibitors. |
| Q37980177 | A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]). |
| Q28545757 | Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors |
| Q41040182 | Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. |
| Q28533587 | In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410 |
| Q36644657 | Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques |
| Q35844509 | Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase |
| Q28538105 | Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy |
| Q36409617 | Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention |
| Q35518190 | Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection |
Search more.